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Abbreviations: 
ACE   Akershus Cardiac Examination   
BMI   Body mass index 
cIMT   Carotid intima-media thickness 
CI   Confidence interval  
CRP   C-reactive protein 
CV   Cardiovascular  
DM   Diabetes mellitus  
eGFR   Estimated glomerular filtration rate  
HbA1c  Glycated hemoglobin 
HDL   High-density lipoprotein 
LA   Linoleic acid 
LDL    Low-density lipoprotein 
PUFA   Polyunsaturated fatty acid  
Std. β-coeff.  Standardized regression coefficient 
Unstd. β-coeff. Unstandardized regression coefficient 
wt%   Weight percentage  
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Abstract 
Background: A high intake of linoleic acid (LA), the major dietary polyunsaturated fatty acid 
(PUFA), has previously been associated with reduced cardiovascular (CV) morbidity and 
mortality in observational studies. However, recent secondary analyses from clinical trials of 
LA-rich diet suggest harmful effects of LA on CV health. 
Methods: A total of 3,706 participants, all born in 1950, were included in this cross-sectional 
study. We investigated associations between plasma phospholipid levels of LA and CV risk 
factors in a Norwegian general population, characterized by a relative low LA and high 
marine n-3 PUFA intake. The main statistical approach was multivariable linear regression. 
Results: Plasma phospholipid LA levels ranged from 11.4 to 32.0 wt%, with a median level 
of 20.8 wt% (interquartile range 16.8-24.8 wt%). High plasma LA levels were associated with 
lower serum low-density lipoprotein cholesterol levels (Standardized regression coefficient 
[Std. β-coeff.] -0.04, p=0.02), serum triglycerides (Std. β-coeff. -0.10, p<0.001), fasting 
plasma glucose (Std. β-coeff. -0.10, p<0.001), body mass index (Std. β-coeff. -0.13, p<0.001), 
systolic and diastolic blood pressure (Std. β-coeff. -0.04, p=0.03 and Std. β-coeff. -0.02, 
p=0.02, respectively) and estimated glomerular filtration rate (Std. β-coeff. -0.09, p<0.001). 
We found no association between plasma LA levels and high-density lipoprotein cholesterol 
levels, glycated hemoglobin, carotid intima-media thickness or C-reactive protein.  
Conclusion: High plasma LA levels were favorably associated with several CV risk factors in 
this study of a Norwegian general population. 
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Introduction 
Linoleic acid (LA) is an essential fatty acid, mainly derived from vegetable oils, nuts, eggs 
and meats (1). It is the major n-6 polyunsaturated fatty acid (PUFA) and the most abundant 
PUFA in the Western diet (1). LA intake has previously been associated with a lower risk of 
cardiovascular (CV) morbidity and mortality in large epidemiological studies (2-4). However, 
recent published secondary analysis from the Sydney Diet Heart Study and Minnesota 
Coronary Experiment have raised concerns, as they report a direct association between diets 
rich in LA and an increase in overall and coronary heart disease mortality (5, 6). One 
proposed mechanism for this observation is an LA-induced increase in oxidized low-density 
lipoprotein (LDL) cholesterol particles, which are highly atherogenic (5, 6). LA has also been 
suggested to promote inflammation by serving as a precursor for arachidonic acid, an n-6 
PUFA that is oxidized to proinflammatory cytokines during eicosanoid metabolism (7). In 
addition, LA reduces the conversion of plant derived n-3 PUFA alpha-linolenic acid to the 
anti-inflammatory n-3 PUFAs eicosapentaenoic and docosahexaenoic acid (7), also found in 
fatty fish and other seafoods.  
The effects of LA intake on CV health have therefore been a matter of discussion and have 
resulted in inconsistent recommendations on LA consumption across regions. While the 
American Heart Association recommends consumption of at least 5% to 10% energy from LA 
intake, the European Food Safety Authority, supported by the French national guidelines, 
recommend 4% (8-10). A recent systemic review, evaluating LA intake in various European 
nations, showed that the European Food Safety Authority recommendations were not met in 
half of the countries included in the study (11). Compared to a modern Western diet, the 
traditional Nordic diet is characterized by a relatively high marine n-3 PUFA and low LA 
consumption (12). 
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Thus, there is a possibility that the LA intake might be lower than optimal also in Norway. 
The average energy intake from total PUFAs (the sum of n-3 PUFAs and n-6 PUFAs) was 
approximately 6% in Norway in 2012 (13), hence the energy intake from LA alone was 
probably lower than American Heart Association’s recommendations. The assessment of how 
a marker of LA consumption is associated with the CV risk profile in a Norwegian general 
population might add new knowledge on the relationship between LA intake and CV health. 
The objective of this study was to investigate associations between plasma LA levels, as an 
estimate of LA intake (14, 15), and multiple CV risk factors. 
 
Materials and methods 
Study population 
The Akershus Cardiac Examination (ACE) 1950 Study is a prospective population-based 
cohort study, evaluating the cardio- and cerebrovascular health of men and women born in 
1950 and living in Akershus County, Norway. The study design and baseline examinations of 
the ACE 1950 Study have previously been described in detail (16). In brief, the Norwegian 
population register was used to identify all eligible individuals in Akershus County, who were 
invited for study participation by letters and subsequent phone calls. Among 5,827 invited 
individuals, 3,706 agreed to participate (64%) (Figure 1). The remaining 2,121 did not 
respond to the study invitation letter or declined participation. Enrollment was performed at 
Akershus University Hospital and Bærum Hospital from September 2012 through May 2015.   
In this article, we present data from a cross-sectional analysis of the baseline examination.  
 
Data collection and procedures  
All participants completed questionnaires on medical history, diet, education, physical 
activity and smoking. Higher education was defined as >12 years of formal education. 
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Smoking habits were classified as current smoker or previous/non-smoker. High physical 
activity was defined as >2 sessions of exercise per week. Alcohol consumption was defined as 
intake of alcohol 2 times per week. Study participants underwent a standardized physical 
examination. Hypertension was defined as mean systolic blood pressure  140 mmHg or 
mean diastolic blood pressure  90 mmHg from three measurements in the sitting position, or 
current use of anti-hypertensive medication. The World Health Organizations definition was 
used to define obesity (body mass index BMI, kg/m2  30) (17). 
Blood samples were obtained after overnight fasting and stored at -80 C until analysis. 
Hypercholesterolemia was defined as total serum cholesterol  6.2 mmol/L or LDL 
cholesterol  4.1 mmol/L (18), or current use of lipid-lowering agents. Diabetes mellitus 
(DM) was defined as both glycated hemoglobin (HbA1c)  6.5% and fasting plasma glucose 
 7.0 mmol/L, self-reported DM or current use of glucose-lowering medications. Chronic 
kidney disease stages 3-5 were defined as estimated glomerular filtration rate (eGFR) 60 
ml/min/1.73m2 using The Chronic Kidney Disease Epidemiology Collaboration equation 
(19). Standard assay was used for the measurement of C-reactive protein (CRP).  
Carotid intima-media thickness (cIMT) was assessed by ultrasound examination of the right 
and left carotid arteries, as previously described (20). Mean cIMT was obtained from the 
average of right and left cIMT measurements.  
  
Plasma phospholipid fatty acid measurement  
Aliquots from stored frozen blood samples were sent to The Lipid Research Center, Aalborg 
University Hospital for plasma fatty acid analysis by gas chromatography. In brief, Folch 
method was used to extract total lipids from serum (21), and the Burge method was used to 
isolate the phospholipid fraction from other lipids (22). The fatty acids were analyzed by a 
Varian 3900 gas chromatograph (Varian, Middleburg, The Netherlands) with 60 m x 0.25 mm 
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capillary columns. Individual fatty acids were identified from their retention time during gas 
chromatography, and quantified as weight percentage (wt%) of total plasma phospholipid 
fatty acids.  
Data on plasma LA levels were missing in 23 participants, either due to insufficient plasma 
volume (n=17) or inadequate plasma fatty acid analysis (n=6) (Figure 1). 
 
Ethical considerations 
All participants gave written informed consent before final enrollment. The study was 
approved by the Norwegian Regional Ethics Committee (September 7th 2011. Ref. number 
2011/1475) and performed in accordance with the Declaration of Helsinki. Registered at 
clinicaltrials.gov, registration number NCT01555411.   
 
Statistical analysis 
Quartiles of plasma LA were used for presentation of demographic and clinical data. Results 
are presented as mean values (standard deviations) for normally distributed data, median 
values (inter quartile ranges) for skewed data (serum triglycerides, fasting plasma glucose, 
HbA1c and CRP) and percentages for categorical data. Between-groups differences were 
assessed by Chi square test for dichotomous variables, Kruskal-Wallis test for skewed 
variables and ANOVA for normally distributed continuous variables. Bivariate associations 
between plasma LA levels and plasma eicosapentaenoic and docosahexaenoic acid levels, 
higher educational level, alcohol consumption, gender, smoking and physical activity are 
presented with Spearman’s correlation (rs). We investigated multivariable adjusted 
associations between plasma LA levels and CV risk factors, after testing for linearity with 
standard methods and restricted cubic spline modelling, the graphical presentation for which 
is presented in Figure 2. For restricted cubic spline modelling, the continuous variable plasma 
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LA levels was subdivided by use of three knots, placed at 10th, 50th and 90th percentile of the 
exposure distribution. Although assumptions for linearity between plasma LA levels and 
serum LDL cholesterol and HbA1c were not fully met, multivariable linear regression was 
performed for these variables. Adjustments were made with for each CV risk factor with 
covariates chosen from a set of predefined candidate variables by least absolute shrinkage and 
selection operator (LASSO) regression (Supplementary table 1). First highly inflated Std. β-
coeff. were penalized towards zero. A tuning parameter lambda, which was chosen for each 
CV risk factor after cross validation, controlled the strength of penalty. Second, during 
variable selection, candidate variables with regression coefficients > 0 after the shrinkage 
process, were included in the final model. All models were constructed using simultaneous 
entry of variables. Skewed variables were truncated to obtain normal distribution, before they 
were entered into the regression models. Because of extreme skewness, CRP was 
logarithmically transformed before it was entered as a variable in the regression analyses. 
Thus, for CRP, the presented unstandardized regression coefficients (Unstd. β-coeff.) and 
corresponding 95% confidence intervals (CI) represent the anti-logarithm of obtained results. 
The table displays Unstd. β-coeff. with corresponding 95% CI, standardized regression 
coefficients (Std. β-coeff.), p-values and explained variance (R2) for the univariable and the 
fully adjusted final models. All statistical calculations were performed using SPSS® version 
25.0 (IBM, NY, US), RStudio® version 1.1.419 and R version 3.4.4 (RStudio Inc., Boston, 




Demographics and clinical characteristics of study participants are presented in Table 1. 
Plasma LA levels ranged from 11.4 to 32.0 wt%, with a median level of 20.8 wt% 
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(interquartile range 16.8 to 24.8 wt%). Participants with high plasma LA levels had lower 
plasma levels of eicosapentaenoic and docosahexaenoic acid (rs = -0.44 and rs = -0.37, 
p<0.001 for both). Higher education (rs = 0.07, p<0.001) and less alcohol consumption (rs = -
0.07, p<0.001) were seen in participants with high plasma LA levels, while no differences 
were observed for gender (rs = -0.01, p=0.62), smoking (rs = -0.03, p=0.09) or physical 
activity (rs = 0.03, p=0.13). Furthermore, a lower prevalence of hypertension, 
hypercholesterolemia, cerebrovascular and coronary artery disease, DM and obesity were also 
seen in participants with high compared to low levels of plasma LA. Moreover, the use of 
antihypertensive-, lipid-lowering and glucose-lowering medications were lower in 
participants with higher plasma LA levels.  
 
Plasma LA levels and CV risk factors   
Cubic spline modeling of associations between plasma LA levels and CV risk factors are 
presented in Figure 2. Except for serum LDL-cholesterol levels and HbA1c, the associations 
between plasma LA levels and CV risk factors were linear. Unadjusted and multivariable 
adjusted associations between plasma LA levels and CV risk factors are presented in Table 2. 
High plasma LA levels were associated with lower serum LDL cholesterol and triglyceride 
levels, while no association was found with serum high-density lipoprotein (HDL) cholesterol 
levels.  
High plasma LA levels were associated with lower fasting plasma glucose. When stratifying 
participants according to DM, plasma LA levels showed a statistically significant association 
fasting plasma glucose in participants without DM (n=3296, Unstd. β-coeff. -0.03 95% CI -
0.03, -0.02, Std. β-coeff. -0.13, p<0.001), while a trend was seen in participants with DM 
(n=309, Unstd. β-coeff. -0.05 95% CI -0.10, 0.02, Std. β-coeff. -0.11, p=0.15). We found no 
associations between plasma LA levels and HbA1c.  
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Plasma LA levels were inversely associated with BMI and systolic and diastolic blood 
pressure (Table 2).  
High plasma LA levels were associated with lower eGFR. Participants were stratified 
according to eGFR levels above or below 60 ml/min/1.73m2. Plasma LA levels were 
inversely associated with eGFR >60 ml/min/1.73m2 (n=3452, Unstd. β-coeff. -0.28 95% CI -
0.40, -0.15, Std. β-coeff. -0.08, p<0.001). In contrast, no association was found with eGFR 
<60 ml/min/1.73m2 (n=141, Unstd. β-coeff. -0.01 95% CI -0.47, 0.46, Std. β-coeff. -0.003, 
p=0.98).  
We found no statistical association between plasma LA levels and cIMT or CRP (Table 2).  
 
When stratifying participants according to educational level and alcohol consumption, 
associations between plasma LA levels and CV risk factors did not change (data not shown).  
 
Discussion 
The main finding of the present study was that high levels of plasma LA were associated with 
lower fasting plasma glucose and BMI. High plasma LA levels were associated with lower 
serum triglyceride levels and systolic blood pressure. We found no association between 
plasma LA levels and CRP.    
 
Plasma LA levels and CV risk factors  
Plasma LA levels and fasting plasma glucose, HbA1c and BMI   
In the present study, we found a lower prevalence of DM among participants in the upper 
quartile of plasma LA levels. High levels of plasma LA were associated with lower fasting 
plasma glucose in individuals without DM, while no statistically significant association was 
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found in participants with DM, in whom most received glucose-lowering medication that 
could possibly confound results. In a pooled analysis of 20 prospective studies, including 
>39,000 participants from 10 different countries, high plasma levels of LA were associated 
with a lower risk of incident type 2 DM (23). These reports, along with our findings, may 
suggest that LA consumption might contribute in prevention of DM. Surprisingly, plasma LA 
levels were not associated with HbA1c. Similar results have been reported in a cross-sectional 
study from the Dutch general population, aged 50-74 (24). Concordant with our findings, they 
found that high plasma LA levels were associated with lower fasting plasma glucose, while 
no associations were found with HbA1c (24). The underlying mechanism by which LA 
influences the glucose-insulin homeostasis is poorly understood. Improved insulin sensitivity 
mediated by LA has been suggested (25). Another possible mechanism could be increased 
glucose consumption related to the upregulation of carnitine shuttle system required for 
mitochondrial -oxidation of long-chain fatty acids, such as LA (26). Increased mitochondrial 
-oxidation after a high intake of long-chain fatty acids has also been suggested to induce 
weight loss (27), which could partly explain the lower prevalence of obesity and lower BMI 
associated with high plasma LA levels in the present study. On the other hand, weight loss 
achieved by increased LA intake in clinical trials has been at the expense of energy from 
carbohydrates (27), and can therefore not be attributed to LA intake alone.  
 
In addition to LA consumption, plasma LA levels are influenced by delta-6 desaturase activity 
regulating the endogenous LA metabolism (28). In a population-based cohort study, 
participants with metabolic syndrome and insulin resistance had higher delta-6 desaturase 
activity and lower serum LA levels compared to control (29). A higher delta-6 desaturase 
activity has also been associated with insulin resistance (30). Hence, we cannot rule out 
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reverse causality bias that could possibly underlie inverse associations between plasma LA 
levels and fasting plasma glucose levels.  
 
Plasma LA levels and CRP 
A concern for harm from a high LA intake has been linked to the potential conversion of LA 
to arachidonic acid, a precursor for inflammatory cytokines. However, this endogenous 
conversion is tightly regulated and has been reported to be less than 0.3% in a tracer study 
with stabile isotopes (31). In a systematic review of human trials, a 6-fold increase in LA 
consumption did not affect plasma or tissue concentration of arachidonic acid (32). 
Furthermore, a high LA intake in clinical trials did not increase inflammatory biomarkers 
such as CRP, interleukin-6, tumor necrosis factor- or plasma fibrinogen (33). In the present 
study, plasma LA levels were not associated with CRP. Thus, our finding does not support the 
proposed proinflammatory nature of LA. It should however be mentioned that we did not 
measure high-sensitive CRP, which is a more reliable marker of low-grade inflammation, 
hence our finding should be interpreted with caution with regards to CRP levels. Furthermore, 
the median CRP level was 1.5 mg/L in our cohort, a level which has been associated with an 
average risk of CV disease among Caucasians in other community-based studies (34).    
Advice to reduce LA intake has also been based on the competition with n-3 PUFAs, as LA 
theoretically can inhibit the conversion of alpha-linolenic acid to eicosapentaenoic acid and 
docosahexaenoic acid (7). However, in humans this conversion is low (<5%) (35), and likely 
of minor importance in a Norwegian general population with a high background consumption 
of marine n-3 PUFAs and a low alpha-linolenic acid intake (12).  
 
Plasma LA levels and serum lipids 
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The relationship between LA and blood lipids is not clearly understood. In a meta-analysis of 
60 clinical studies, the substitution of LA for carbohydrates reduced serum LDL cholesterol 
and triglyceride levels (36). Similarly, substituting saturated fatty acids with LA, in a clinical 
trial in men with dyslipidemia, resulted in a decreased production of LDL particles (37). 
These reports indicate possible lipid-lowering properties of LA, but should be interpreted with 
caution as they were obtained at the expense of carbohydrates and saturated fatty acids. One 
suggested mechanism by which LA influences blood lipids is increased clearance of 
triglyceride rich particles, the upstream of LDL cholesterol production (37). Furthermore, a 
high intake of LA has shown to increase lipoprotein lipase activity in experimental studies 
(38), an enzyme involved in hydrolysis of triglycerides. In the present study, high plasma LA 
levels were associated with lower serum LDL cholesterol and triglyceride levels. 
Furthermore, participants in the upper compared with the lower quartile of plasma LA levels 
had a lower prevalence of hypercholesterolemia and used lipid-lowering drugs less often. 
However, the inverse associations between plasma LA levels and serum LDL cholesterol in 
the present study must be interpreted with caution for several reasons. First, assumptions for a 
linear association between plasma LA and serum LDL cholesterol levels were not met. 
Second, participants in the upper compared to lower quartile of plasma LA levels had higher 
serum LDL cholesterol levels. Finally, in our cohort, plasma LA and serum LDL cholesterol 
levels seemed to have an inverted U-shaped relationship (Figure 2), which does not appear 
biological plausible. Thus, we speculate that this association might have been confounded by 
factors we have not been able to identify and adjust for in our analyses.  
Plasma LA levels were not associated with serum HDL cholesterol levels, consistent with a 




Plasma LA levels and cIMT, blood pressure and kidney function 
cIMT is a validated surrogate marker of future CV events (40). The association between 
serum LA and cIMT was evaluated in a Spanish population, with a high background 
consumption of vegetable oils as a part of the Mediterranean diet (41). In that cross-sectional 
study, serum LA levels were not associated with cIMT. Similarly, in our cohort, with a low 
background intake of LA, we did not find an association with cIMT. Furthermore, we found 
only a weak association between plasma LA levels and blood pressure, and no association 
with serum HDL cholesterol levels, which are considered strong predictors of cIMT 
progression (42, 43). Finally, a recent meta-analysis reported no effect on blood pressure from 
LA intake (39).  
Data on LA intake and kidney function are scarce. A prospective cohort study found less 
decline in renal function at 3-year follow-up in participants with higher plasma LA levels at 
baseline (44). In the present study, plasma LA levels were not associated with eGFR <60 
ml/min/1.73m2, suggesting no benefits for renal function in participants with chronic kidney 
disease stages 3-5.  
 
Plasma LA levels and general health and lifestyle  
Participants in the upper quartile of plasma LA levels were generally healthier than the 
remaining cohort, with a lower prevalence of hypertension, hypercholesterolemia, DM, 
obesity, cerebrovascular and coronary artery disease. This was also reflected by a lower use of 
antihypertensive-, lipid-lowering and glucose-lowering medications among these participants. 
Plasma LA levels were not associated with factors such as smoking habits or physical 
activity, and associations with CV risk factors remained unchanged when participants were 
stratified according to educational level and alcohol consumption. Thus, the findings signal 
that high plasma LA levels may favorably influence CV risk factors. High plasma LA levels 
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were associated with overall healthier lifestyle producing a confounder effect, for which we 
attempted to adjust for in the statistical analysis. However, residual confounding from 
variables not included in the regression models might still have influenced results, leading to 
a possible overestimation of associations between plasma LA levels and CV risk factors. Low 
plasma LA levels have previously been associated with higher BMI, fasting plasma glucose, 
triglycerides and alcohol consumption (45). Similar findings were reported in statin users 
compared to non-users (46). A possible explanation could be altered plasma fatty acid 
composition in individuals with adverse metabolic risk profile, in which case plasma LA level 
might serve as a marker of cardiometabolic health. Thus, in the present study, we cannot rule 
out the possibility that our findings have been influenced by revers causality bias.  
 
Strengths and limitations  
In this study we measured plasma LA levels as an estimate of LA intake, which is a more 
reliable marker than self-reported intake from dietary interviews, which are often influenced 
by recall bias. To our knowledge, this is the largest cohorts in a Norwegian general population 
where plasma LA levels have been measured by gas chromatography. The study population 
was well-described and had little missing data. In addition, all participants were born in 1950, 
thus removing age as a confounding factor.  
There are also several limitations. The cross-sectional study design does not allow for any 
conclusion on causality. Dietary data on LA consumption was not available for this study. 
Plasma phospholipid PUFA levels do not represent long-term fatty acid intake as accurately 
as erythrocyte membrane or adipose tissue PUFA levels. However, for LA level estimates, 
plasma is an equally representative compartment as erythrocyte membrane or adipose tissue 
(14). Despite careful adjustments for covariates, we cannot rule out residual confounding 
influencing associations between plasma LA levels and CV risk factors. Furthermore, we 
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acknowledge that our results are characterized by weak regression coefficients and that 
statistically significant associations between plasma LA levels and CV risk factors might have 
been driven by the large sample size. However, for the purpose of proposing hypothesis 
regarding the impact of LA consumption on CV health, we consider our results to be 
applicable to a Nordic general population. Our results might not apply to other regions, 
especially those with a high LA consumption. Finally, as all the participants in the ACE 1950 
Study were born in 1950, our results might not apply to other age groups.   
 
Conclusion 
We found favorable associations between high plasma LA levels and various CV risk factors 
in this cross-sectional study of Norwegian individuals born in 1950. 
Well-designed clinical trials are needed to study the effect of an increased LA intake on CV 
risk factors.   
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Figure legends   
 
Figure 1 
Flowchart of the inclusion of study participants.  
 
Figure 2 
Univariate associations between plasma linoleic acid levels (x-axis) and CV risk factors (y-
axis), modeled as restricted cubic spline. We used three knots, placed at 10th, 50th and 90th 
percentile of plasma linoleic acid levels, measured in weight percentage of total plasma 


















Table 1. Characteristics of study participants according to quartiles of plasma linoleic 
acid levels. 
 
 All patients Quartile 1 Quartile 2 Quartile 3 
 
Quartile 4 p  
Linoleic acid level, wt% 11.4-32.0 ≤18.74 18.75–20.82 20.83-22.77 
 
≥22.78  
Number of participants  3683 922 919 923 
 
919  
Age, months 767 (7.8) 768 (7.9) 767 (7.7) 767 (7.9) 
 
766 (7.4) <0.001 












Daily whole wheat bread 





EPA, wt% 2.6 (1.4) 3.4 (1.7) 2.8 (1.2) 2.3 (1.1) 
 
1.9 (0.9) <0.001 
 
DHA, wt% 5.5 (1.4) 6.2 (1.6) 5.7 (1.4) 5.3 (1.2) 
 
4.8 (1.2) <0.001 
ALA, wt% 0.26 (0.1) 0.22 (0.1) 0.25 (0.1) 0.27 (0.1) 
 
0.29 (0.1) <0.001 
AA, wt% 9.2 (2.1) 10.3 (2.4) 9.6 (1.9) 8.9 (1.6) 
 
8.1 (1.6)  <0.001 




Alcohol consumption, (≥ 2 





Physical activity (≥ 2 times 








Systolic blood pressure, 
mmHg 138 (19) 139 (19) 139 (19) 137 (18) 
 
 
137 (19)  0.01 
 
Diastolic blood pressure, 
mmHg 77 (10) 78 (10) 77 (10) 77 (10) 
 
 
76 (10) 0.11 
Total cholesterol, mmol/L 5.4 (1.1) 5.2 (1.2) 5.5 (1.1) 5.6 (1.1) 
 
5.5 (1.0) <0.001 
HDL cholesterol, mmol/L 1.5 (0.5) 1.5 (0.5) 1.5 (0.5) 1.6 (0.5) 
 
1.6 (0.5) <0.001 
LDL cholesterol, mmol/L 3.3 (1.0) 3.0 (1.0) 3.4 (1.0) 3.4 (0.9) 
 






















































Body mass index (BMI), 
kg/m2 27.1 (4.4) 28.1 (4.4) 27.3 (4.3) 27.1 (4.5) 
 
 
26.0 (4.3) <0.001 
eGFR, ml/min x 1.73m2  83 (12.0) 84 (12.3) 83 (11.8) 84 (12.0) 
 
82 (11.5) 0.008 
cIMT, mm  0.73 (0.1) 0.74 (0.1) 0.73 (0.1) 0.73 (0.1) 
 


















Hypertension, % 62.0 72.6 62.5 59.5 
 
53.3 <0.001 
Hypercholesterolemia, %  52.6 71.0 58.2 47.1 
 
33.9 <0.001 
Cerebrovascular disease, %  3.7 5.1 4.1 4.1 
 
1.6  <0.001 
Coronary artery disease, %  7.0 13.7 6.7 4.9 
 
2.8 <0.001 
Diabetes mellitus, % 8.5 12.9 9.4 6.3 
 
5.4 <0.001 




CKD stages 3-5 (eGFR <60 




Medication, %     
 
 
      Diuretics 3.1 4.3 3.2 2.4 
 
2.4 0.05 
      Beta blockers 13.4 20.8 13.2 11.4 
 
8.1 <0.001 
      Calcium channel blockers 8.1 12.1 7.7 8.8 
 
3.9 <0.001 
      ACEi or ARB 26.9 36.2 26.3 25.6 
 
19.6 <0.001 
      Lipid-lowering drugs 26.1 49.9 27.9 17.2 
 
9.6 <0.001 




Results are presented as percentage for categorical data and mean value (standard deviation) 
for continuous data. Differences between groups were evaluated using Chi square for 
dichotomous data, the Kruskal-Wallis test for triglycerides, fasting plasma glucose, HbA1c 
and CRP, and ANOVA for other continuous data. 
Abbreviations: EPA: Eicosapentaenoic acid. DHA: Docosahexaenoic acid. ALA: Alpha-
linoleic acid. AA: Arachidonic acid. HDL: High density lipoprotein. LDL: Low density 
lipoproteins HbA1c: Hemoglobin A1c. BMI: Body mass index. eGFR: Estimated glomerular 
filtration rate (CKD-EPI formula). cIMT: Carotid intima-media thickness. CRP: C-reactive 
protein. CKD: Chronic kidney disease. ACEi: Angiotensin converting enzyme inhibitor. 






Table 2. Associations between plasma linoleic acid levels and cardiovascular risk factors. 
 
Univariable linear regression analysis 
Cardiovascular risk factors       n               Unstd. β-coeff. (95% CI) Std. β-coeff. p R2 
HDL cholesterol, mmol/L 3680 0.01 (0.01, 0.02) 0.08 <0.001 0.01 
LDL cholesterol, mmol/L 3657 0.05 (0.04, 0.06) 0.14 <0.001 0.02 
Triglycerides, mmol/L  3680 -0.04 (-0.05, -0.03) -0.18 <0.001 0.03 
Fasting glucose, mmol/L 3675 -0.06 (-0.07, -0.05) -0.18 <0.001 0.03 
HbA1c, %   3669 -0.02 (-0.02, -0.01) -0.08 <0.001 0.01 
BMI, kg/m2  3683 -0.27 (-0.31, -0.23)  -0.18 <0.001 0.03 
SBP, mmHg 3679 -0.40 (-0.61, -0.20) -0.06 <0.001 0.004 
DBP, mmHg 3679 -0.12 (-0.23, -0.01) -0.04 0.03 0.001 
eGFR, ml/min x 1.73m2 3664 -0.21 (-0.34, -0.07) -0.05 0.002 0.002 
cIMT, mm   3661 -0.002 (-0.003, -0.001) -0.05 0.002 0.002 
CRP, mg/L 3669 -1.01 (-1.02, -1.01) -0.06 <0.001 0.003 
Multivariable linear regression analysis 
Cardiovascular risk factors       n               Unstd. β-coeff. (95% CI) Std. β-coeff. p R2 
HDL cholesterol, mmol/L a 3609 0.0001 (-0.005, 0.005) 0.00 0.98 0.30 
LDL cholesterol, mmol/L b 3646 -0.01 (-0.02, -0.002) -0.04 0.02 0.28 
Triglycerides, mmol/L c 3609 -0.02 (-0.03, -0.02) -0.10 <0.001 0.19 
Fasting glucose, mmol/L d 3605 -0.03 (-0.04, -0.02) -0.10 <0.001 0.36 
HbA1c, % e  3599 0.00 (-0.01, 0.01) -0.002 0.90 0.41 
BMI, kg/m f 3612 -0.20 (-0.25, -0.15)  -0.13 <0.001 0.16 
SBP g 3609 -0.25 (-0.47, -0.03) -0.04 0.03 0.03 
DBP h 3609 -0.14 (-0.25, -0.02) -0.02 0.02 0.12 
eGFR, ml/min x 1.73m2 i 3593 -0.37 (-0.51, -0.23) -0.09 <0.001 0.04 
cIMT, mm j  3635 0.000 (-0.001, 0.001) -0.01 0.73 0.07 
CRP, mg/L k  3603 -1.01 (-1.02, 1.00) -0.03 0.06 0.07 
      
a Gender, smoking, diabetes mellitus, BMI, lipid-lowering drugs, glucose-lowering drugs, hypertension, physical 
activity, higher education, age (months), alcohol consumption. 
b Gender, diabetes mellitus, BMI, lipid-lowering drugs, glucose-lowering drugs, higher education, age (months). 
c Gender, smoking, diabetes mellitus, BMI, lipid-lowering drugs, glucose-lowering drugs, hypertension, physical 
activity, higher education, age (months), alcohol consumption. 
d Gender, smoking, BMI, lipid-lowering drugs, glucose-lowering drugs, hypertension, physical activity, higher 
education, age (months), alcohol consumption. 
e Gender, smoking, BMI, lipid-lowering drugs, glucose-lowering drugs, hypertension, physical activity, higher 
education, age (months), alcohol consumption. 
f Gender, smoking, diabetes mellitus, lipid-lowering drugs, hypertension, physical activity, higher education, age 
(months), alcohol consumption. 
g Gender, smoking, diabetes mellitus, BMI, lipid-lowering drugs, physical activity, higher education, age 
(months), alcohol consumption, antihypertensive drugs. 
h Gender, smoking, diabetes mellitus, BMI, lipid-lowering drugs, glucose-lowering drugs, physical activity, 
higher education, age (months), alcohol consumption, antihypertensive drugs. 
i Gender, smoking, diabetes mellitus, BMI, lipid-lowering drugs, hypertension, physical activity, higher 
education, age (months), alcohol consumption. 
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j Gender, smoking, BMI, glucose-lowering drugs, hypertension, age (months). 
k Gender, smoking, diabetes mellitus, BMI, lipid-lowering drugs, hypertension, physical activity, higher 
education, age (months). 
 
Unstandardized β coefficients (Unstd. β-coeff.) with corresponding 95% confidence intervals 
(CI), standardized β coefficients (Std. β-coeff.), p-values and explained variance (R2) are 
given for plasma LA in the univariable analysis and for the fully adjusted multivariable 
model.  
Abbreviations: HDL: High-density lipoprotein. LDL: Low-density lipoprotein. HbA1c: 
Hemoglobin A1c. BMI: Body mass index. SBP: Systolic blood pressure. DBP: Diastolic 
blood pressure. eGFR: Estimated glomerular filtration rate. cIMT: Carotid intima-media 


































Fig 2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
